This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2004 Jul;59(7):698-700.

doi: 10.1111/j.1398-9995.2004.00548.x.

Anti-IgE: a significant breakthrough in the treatment of airway allergic diseases

R Louis

PMID: 15180755
DOI: 10.1111/j.1398-9995.2004.00548.x

Editorial

Anti-IgE: a significant breakthrough in the treatment of airway allergic diseases

R Louis. Allergy. 2004 Jul.

. 2004 Jul;59(7):698-700.

doi: 10.1111/j.1398-9995.2004.00548.x.

Author

R Louis

PMID: 15180755
DOI: 10.1111/j.1398-9995.2004.00548.x

No abstract available

PubMed Disclaimer

Comment on

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Ayres JG, et al. Allergy. 2004 Jul;59(7):701-8. doi: 10.1111/j.1398-9995.2004.00533.x. Allergy. 2004. PMID: 15180756 Clinical Trial.
Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, Fox H, Surrey K. Vignola AM, et al. Allergy. 2004 Jul;59(7):709-17. doi: 10.1111/j.1398-9995.2004.00550.x. Allergy. 2004. PMID: 15180757 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley